SCHEMBL3539636

SCHEMBL3539636

CC1CCN(c2cc(N3CCNCC3)ccc2NC(=O)C(F)(F)F)CC1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 11/20 0.61
NTRK1 P04629 1/20 0.51
KIT P10721 1/20 0.51
AXL P30530 1/20 0.51
FLT3 P36888 1/20 0.51
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
ALDH1A1 P00352 3/20 0.42
GAA P10253 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
HSP90AA1 P07900 1/20 0.42
PAX8 Q06710 1/20 0.42
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3543649 0.83 CSF1R (0.66) CSF1RNTRK1KITAXLFLT3
Trifluoroacetic Acid SCHEMBL3539638 0.81 CSF1R (0.50) CSF1RNTRK1KITAXLFLT3
SCHEMBL3539481 0.80 CSF1R (0.54) CSF1RNTRK1KITAXLFLT3
SCHEMBL23293562 0.79 CSF1R (0.70) CSF1RNTRK1KITAXLFLT3
SCHEMBL13767463 0.79 CSF1R (0.78) CSF1RNTRK1KITAXLFLT3
SCHEMBL13405642 0.78 CSF1R (0.81) CSF1R
SCHEMBL31157978 0.78 CSF1R (0.81) CSF1R
SCHEMBL3070911 0.78 NPSR1 (0.65) CSF1RMEN1KMT2ANPC1RAB9A
Trifluoroacetic Acid SCHEMBL3539634 0.77 CSF1R (0.46) CSF1RNTRK1KITAXLFLT3
SCHEMBL13405738 0.76 CSF1R (1.00) CSF1RNTRK1KITAXLFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
EP-1807407-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP disclosed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US disclosed
WO-2006047504-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES CSF1R 34/4885NTRK1 143/4885KIT 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.